Emmanuel J Favaloro/LinkedIn
Aug 21, 2025, 14:55
Emmanuel Favaloro on DOACs Versus Warfarin in the COVID19 Era
“Did the COVID19 pandemic push the use of DOACs to the lead in the ‘anticoagulant race’, and ahead of warfarin?
Well, yes and no.
Depends on where you live. Check out this Commentary in Seminars in Thrombosis and Hemostasis.
Just released online.
Enjoy!”
Stay informed with Hemostasis Today.
-
Oct 29, 2026, 12:17Bridget King: IBM Employees Support Blood Donation Efforts
-
Oct 29, 2026, 12:08Georgina Pearson: A Promising Blood Donation Partnership With Missed Potential
-
Oct 29, 2026, 11:59Dianne E. van der Wal: Cryopreserved Platelets in Transfusion Medicine
-
Oct 29, 2026, 11:50Denis Oduor: Dengue-Associated Thrombocytopenia and the Risk of Bleeding
-
Oct 29, 2026, 11:42Akshat Jain: Thrombin Generation and Factor VIII Equivalence With Mim8
-
Oct 28, 2026, 23:39Paul Tortland: What a New PRP Study Really Tells Us About Knee Osteoarthritis
-
Oct 28, 2026, 23:34Jawad Derbas: Comparing Mechanical and Pharmacomechanical VTE Prophylaxis in Spine Surgery
-
Oct 28, 2026, 23:31Giulio Maria Pasinetti: Aspirin Use Linked to Lower Dementia Risk in Older Adults With Specific Genetic Characteristics
-
Oct 28, 2026, 23:27Ralf Ludwig: Targeting Neutrophil-Driven Autoimmunity Through CDK Inhibition